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Abstract
Tuberculosis (TB) is a highly contagious bacterial infection caused by Mycobacterium 
tuberculosis (MTB), affecting about 1/3rd of the world population and being responsible 
for lot of deaths worldwide, despite the progress achieved in the diagnosis and treat-
ment fields. TB can affect the peritoneum, the TB ascites being a concern for physicians, 
especially when dealing with immunocompromised patients. The clinical presentation of 
TB ascites is challenging, due to nonspecific symptoms that make confusion with other 
diseases and the late results of cultures from ascites. The late diagnosis leads to a delayed 
treatment and high mortality. This manuscript describes recent tools used for early diag-
nosis in TB ascites. Molecular methods based on mycobacterial nucleic acid amplification 
tests (NAATs), polymerase chain reaction (PCR) detecting minimal amounts of bacterial 
DNA, or interferongamma release assays (IGRA) and biochemical methods such as the 
serum-ascites albumin gradient (SAAG) <1.1 g/dL, ratio between lactic dehydrogenase 
(LDH) in ascites fluid/serum total protein (TP) ratio of 0.5 and fluid ascites/serum LDH 
ratio of 0.6, and adenosine deaminase activity (ADA) > 40 UI/ml were recently considered 
more accurate diagnostic procedures. These methods allow a rapid and accurate differ-
ential diagnosis of ascites fluid, making possible the early treatment with appropriate 
drugs.
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1. Introduction
Tuberculosis (TB) is a dangerous infection affecting about one third of the world population 
despite the availability of affordable and effective chemotherapy, remaining one of the major 
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causes of death from a single infectious agent worldwide. The most affected organ is the lung. 
It is preventable through Bacillus of Calmette and Guérin (BCG) vaccination and curable with 
antituberculous drugs.
Tuberculosis is a serious and highly contagious bacterial infection which in humans is usually 
caused by bacteria called Mycobacterium tuberculosis (MTB), a member of the Mycobacteriaceae 
family. This complex also includes M. bovis and M. africanum. M. bovis is more frequently found 
in cattle and other animals, but it’s also responsible for some cases in humans. M. africanum 
is more common in West African countries. Mycobacterial infection is spread through the air 
from one person to another and causes active disease or latent infection [1].
The absolute number of incident cases has been decreasing since the early 2000s. The low-
est incidence rate is found in high-income countries including the United States of America, 
Canada, New Zealand, Western Europe, and Australia. The largest number of incident cases 
is found in low- and middle-income countries. In 2015, 61% of the new cases occurred in Asia, 
followed by 26% new cases in Africa (Figure 1) [2].
The HIV infection is the prevalent risk factor for the development of TB because HIV alters the 
pathogenesis of TB by producing a progressive decline in cell-mediated immunity and raises 
the chances of extrapulmonary involvement [3, 4].
Tuberculosis is a disease which typically involves the respiratory system, being characterized 
by the growth of tubercles in tissues, but it can affect any other organ, in which case it’s called 
extrapulmonary tuberculosis (EPTB) and usually results from hematogenous dissemination, 
being particularly present in immunocompromised patients. In some cases the infection directly 
extends from an adjacent organ. The most common sites of extrapulmonary tuberculosis are the 
lymph nodes, abdomen, bones and joints, pleura, spinal cord, and brain [5, 6].
Figure 1. Worldwide incidence of TB infections.
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Abdominal tuberculosis is a common form of extrapulmonary tuberculosis. The infec-
tion involving M. tuberculosis or M. bovis could be the result of a primary infection or the 
reactivation of a latent focus in immunocompromised patients. The spread of abdominal 
tuberculosis can be hematogenous or can result from direct contact with primary focus 
or ingestion of sputum containing bacilli from the active pulmonary focus. This form of 
EPTB affects the peritoneum, the gut, the abdominal lymph nodes, and sometimes, less 
frequently, the parenchymatous organs in the abdomen like the spleen, liver, and pancreas 
leading to severe complications. There are three types of abdominal tuberculosis: ascitic, 
obstructive, and glandular. Diagnosis can be achieved through different methods: ultra-
sound of the abdomen, CT/MRI scans, biopsies of the suspected organ, endoscopy, and 
various function tests.
Peritoneal tuberculosis is an uncommon site of extrapulmonary infection caused by M. tuber-
culosis. Patients susceptible of developing EPTB are those with malignant diseases, HIV infec-
tion, diabetes, and cirrhosis or patients treated with antitumor necrosis factor (TNF) agents 
or peritoneal dialysis. Peritoneal TB is divided into three types: the wet ascitic type, the fixed 
fibrotic type, and the dry plastic type. The wet ascitic type is more common and is associated 
with large amounts of free or loculated fluid in the abdomen. The high attenuation of the 
ascites in abdominal ultrasound is thought to be due to high protein and cellular content. 
Associated peritoneal enhancement is usually present.
Infection occurs frequently following reactivation of latent tuberculous in the peritoneum from 
hematogenous spread from a primary lung focus. It can also occur via hematogenous spread 
from active pulmonary or miliary TB. Not so often, the organisms enter the peritoneal cavity 
transmurally, from an infected small intestine or contiguously from tuberculous salpingitis. 
Over time, the visceral and parietal peritoneum becomes studded with tubercles [7–9].
2. Definition
Ascites is defined as an abnormal accumulation of fluid in the peritoneal cavity, the presence 
of serous fluid between the visceral and parietal peritoneum. The word ascites is derived from 
the ancient Greek word “askos” meaning a bag or a sack. Under normal circumstances, the 
amount of peritoneal fluid depends on a balance between plasma flowing into and out of the 
blood and lymphatic vessels. This balance, once being disrupted, leads to abnormal accumula-
tion of fluid [10]. Ascites can be a consequence or a complication of infections, malignancy, and 
many severe diseases: cardiac, endocrine, hepatic, or renal. The prognosis is usually poor, but 
it depends on the underlying causes. Laboratory tests of ascitic fluid, clinical, paraclinical, and 
pathological data are required for the differential diagnosis.
Tuberculous ascites, one of the clinical signs of abdominal TB, implies accumulation of fluid 
in the abdomen, a swollen abdomen, and slightly raised tubercles of 1–2 mm all over the peri-
toneum. In EPTB, ascites develops secondary to “exudation” of proteinaceous fluid from the 
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tubercles, similar to the mechanism leading to ascites in patients with peritoneal carcinomato-
sis, and it’s often misdiagnosed in elderly patients. Most patients with tuberculous peritonitis 
have ascites at the time of diagnosis, while the rest present the advanced phase, the dry or 
fibroadhesive form of the disease [11, 12].
3. Clinical manifestations
Tuberculous peritonitis is a subacute disease, and its symptoms evolve over a period of several 
weeks or months.
The insidious onset of this condition and the fact that the diagnosis is rarely suspected explains 
why patients have symptoms for more than 4 months before the diagnosis is established. 
Tuberculous peritonitis should be considered in any patient presenting with several weeks 
of abdominal pain, fever, and weight loss. Systemic and constitutional manifestations are 
common. Symptoms may be mild, with fatigue, abdominal pain, and tenderness, or severe 






The clinical presentation of TB ascites is challenging, since it is nonspecific and can be con-
fused with a plethora of other infectious or noninfectious diseases, leading to a delayed diag-
nosis and treatment which are major factors that contribute to the high mortality of TB.
Another situation that contributes to a delayed diagnosis is the presence of multiple comor-
bidities such as HIV/AIDS, cirrhosis, uremia, or other chronic conditions. Additional illness 
results in atypical presentation of TB ascites which render the symptoms more difficult to 
identify and distinguish. Moreover, in elderly patients, clinical manifestation is minimal with 
abdominal discomfort, constipation, or fatigue, symptoms that most people tend to ignore as 
minor or non-perilous (Figure 2) [14, 15].
Figure 2. Factors associated with delayed diagnosis.
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4. Diagnosis
Due to the fact that the nature of this disease is insidious, the diagnosis represents a challenge 
for clinicians. With the ever-increasing demographic shifts, more cases are now detected in 
areas where TB was a rarity until present. Unless a high degree of suspicion is maintained, the 
diagnosis can easily be missed or delayed [12].
Diagnostic techniques and procedures include:
• Clinical observation
• Imaging techniques: ultrasound, CT/MRI
• Laboratory tests
• Ascites fluid microbiologic and biochemical analysis
Generally, diagnosis is based on clinical suspicion, imaging of tuberculous infected zone, and 
detection of M. tuberculosis in ascitic fluid using acid-fast bacillus staining or culturing. The sensi-
tivity of standard diagnostic methods such as Ziehl-Neelsen staining of smears and Lowenstein-
Jensen culture done from ascitic fluid is very low for the diagnosis of abdominal TB. Ziehl-Neelsen 
staining of the ascitic fluid for mycobacterial detection is positive in only about 3% of the cases 
with proven TB peritonitis. Detection of mycobacteria requires the presence of more than 5000 
bacilli/mL of specimen. In comparison, for positive culture, the presence of at least 10 organisms 
is considered to be sufficient. For a successful detection, culture methods based on a combination 
of liquid or biphasic media, together with solid media, are necessary [16, 17].
Nucleic acid amplification tests (NAATs) are molecular diagnostic methods based on ampli-
fication of mycobacterial nucleic acid. These are rapid methods that provide results within a 
day, and they are more specific and sensitive than Acid-Fast Bacillus Smear (AFB) smear. Albeit 
NAATs were originally designed for respiratory specimens, they can also be used on speci-
mens from other TB sites like ascitic fluid samples, but this technique is still under evaluation.
Ascites of TB peritonitis obtained through ultrasound-guided paracentesis is an exudative type, 
and macroscopically its appearance is chylous and cloudy or turbid. Biochemically, the serum-
ascites albumin gradient (SAAG) is now considered a more sensitive and specific measure than 
the ascitic total protein concentration which has been used for many years, in differentiating the 
ascites due to portal hypertension from ascites due to other pathophysiological mechanisms, 
such as tuberculous ascites which has a SAAG <1.1 g/dL and total proteins >3–4 g% [18, 19]. 
Combining LDH with total protein analysis has been explored for ascitic fluid. The cutoff val-
ues for three parameters in the ascitic fluid for differentiation between hepatic and non-hepatic 
ascites are as follows: LDH of 400 Sigma units, fluid/serum total protein (TP) ratio of 0.5, and 
fluid/serum LDH ratio of 0.6. The presence of any two of these three findings is usually associ-
ated with TB; the absence of all three indicates a hepatic cause [20].
Glucose concentration in the ascitic fluid, under normal conditions, is similar to that in the 
serum. Ascitic glucose concentration decreases due to consumption by bacteria, white blood 
cells, or cancer cells in the fluid in TB peritonitis. Ascitic glucose concentration is lower than 
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normal in TB ascites, which makes it an indicator in differentiating tuberculosis from other 
diseases, such as cirrhosis. The ascitic/blood glucose ratio is a useful test in differentiating TB 
peritonitis from other causes of ascites [18].
Ascitic fluid adenosine deaminase activity (ADA) is considered a more sensitive and specific 
method used for early diagnosis of TB ascites. Even if the full physiological role of ADA is 
not yet completely understood, it is known that ADA values are notably higher (>40 U/L) in 
patients with TB ascites [21–23].
Non-biochemical tests of ascitic fluid, including cell counts, bacterial culture, and polymerase 
chain reaction (PCR), have an important role in diagnosing the cause of ascites.
The total cell count in tuberculous ascites is 150–4000/μL, and the cytologic examination 
shows over 70–80% lymphocytes and more than 250 leucocytes/mm3 (Table 1).
The sensitivity of direct microscopic smear detection of acid-fast bacilli in the ascitic fluid 
(0–6%) and ascitic fluid mycobacterial culture (20–35%) is low, and because of the delay in 
obtaining the results of mycobacterial cultures of ascitic fluid, the mortality is high, and the 
value of these tests in the differential diagnosis of ascites is limited.
Recently, a new approach to the fast diagnosis of bacterial infections emerged, including 
tuberculosis. The advanced molecular techniques provided a new method represented by 
PCR which can detect minimal amounts of bacterial DNA and improves the rates of bacterial 
identification from 4 to 6 weeks for microbiological cultures to 24 hours. In diagnosing TB 
effusions, PCR appears to be an ideal tool, with 94% sensitivity and 88% specificity, becoming 
a rapid and reliable method for identification of infectious ascites [24].
The tuberculin skin testing (TST or purified protein derivative (PPD) skin test) is controversial, 
despite the high specificity of this test which is between 95 and 99%. Skin testing is currently 
used only for detection of latent infection because of its low sensitivity and low positive predic-
tive value. At the moment, there are no recommendations for using this test to diagnose active 
Type Exudative
Appearance Chylous and cloudy/turbid
Total cell count 150–4000/μL
Leucocytes >250/mm3
Lymphocytes >70–80%





Table 1. Characteristics of tuberculous ascites.
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disease like tuberculous peritonitis. At best, tuberculin skin testing can only offer auxiliary 
information. Several studies have reported positivity rates ranging between 24 and 100% with 
no significant difference between high and low endemicity areas. Currently, the recommenda-
tions about the cut point for the induration differ depending on the risk scale. For patients at 
low risk, the cut point is at 15 mm; in cases of moderate risk, the cut point is 10 mm, and for 
those at high risk, the cut point is 5 mm. Generally, about 50% of the patients would have false-
negative reactions to this test, suggesting the fact that it has many potential sources of error. 
In conclusion, anergy testing may yield confusing information and is no longer recommended 
for diagnosis [25].
A great scientific advance has been the development of an IFN-c-based test with an 89% 
sensitivity, which is a quantitative in vitro assay evaluating the cell-mediated immune 
response to M. tuberculosis and has excellent agreement with tuberculin skin testing. The 
principle of this test is that previously sensitized T lymphocytes release IFN-c in response 
to stimulation by purified protein derivative (PPD).
In the past few years, the tuberculin skin test has been replaced by T-cell-based interferon-gamma 
release assay (IGRA) which is more sensitive and more specific. IGRA is an in vitro test used in 
all circumstances in which the TST is currently used, including evaluation of immigrants, sur-
veillance programs, or contact investigations [26]. There are three commercially available IFN-γ 
tests: QuantiFERON-TB Gold assay (QFN-Gold), QuantiFERON-TB Gold In-Tube assay (QFN-
G-IT), and T-SPOT.TB assay. They are rapid immunodiagnostic tests that can detect interferon-γ 
(IFN-γ) produced by lymphocytes in response to Mycobacterium tuberculosis (MTB). T-SPOT.TB 
test is a blood IFN-γ assay that measures the number of IFN-γ-producing T cells by identifying 
IFN-γ release when stimulated by MTB-specific antigens, including early secretory antigenic tar-
get 6 and culture filtrate protein 10, using enzyme-linked immunospot assay. QuantiFERON-TB 
Gold test is the predecessor of QuantiFERON-TB Gold In-Tube test, and they both measure pro-
duction of IFN-γ in culture supernatant using enzyme-linked immunosorbent assay (ELISA). 
This measurement is possible by circulating T cells in whole blood being challenged with M. 
tuberculosis-specific antigens. The advantage of blood IGRA tests over tuberculin skin tests is 
the fact that IGRAs do not cross-react with the Bacillus of Calmette and Guérin (BCG) vaccine 
antigens, but suboptimal results can be possible in diagnosing EPTB because they aren’t able to 
distinguish latent infection from active disease [27]. According to some researches, M. tuberculo-
sis antigen-specific T cells may accumulate at infection sites; therefore, investigating body fluid 
IGRAs may increase the accuracy of EPTB diagnosis [28, 29].
Imaging techniques used for detection of TB ascites are ultrasound and computed tomography. 
These methods also increase the accuracy of several procedures like paracentesis or peritoneal 
biopsies, providing a safer and affordable replacement to diagnostic laparoscopy [30].
Ultrasound is the most sensitive and reliable method of detecting ascites, guiding paracentesis 
and monitoring the effects of therapy. It can detect even small volumes of fluid (as little as 
100 ml of fluid could be detected). Ascites is usually seen as an anechoic space. In TB asci-
tes, particulate matter within the ascitic fluid or fine, mobile strands, representing echogenic 
debris, can be detected. Less commonly, the ultrasound can reveal calcifications in the walls 
of encysted ascitic fluid [12].
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On computed tomography the ascitic fluid has high attenuation values, between 20 and 45 HU, 
and the peritoneum is symmetrically thickened and nodular. Frequently, an early sign of abdom-
inal TB is a thickened mesentery (>15 mm) with mesenteric lymph nodes.
Many studies concluded that ultrasonography and computed tomography are complemen-
tary to each other in detecting TB ascites, as they provide different details. CT focuses on the 
peritoneum and omental and mesentery involvement, and the ultrasound shows fine, mobile 
septations (Figure 3) [31].
However, the only certain way to diagnose TB ascites is the histological examination. Various 
methods that include excision, laparoscopy, needle biopsy and ultrasound-guided biopsies, 
endoscopy, computed tomography (CT), or endoscopic ultrasound are used to establish the 
Figure 3. Circumferential parietal thickness, with an edematous appearance of the appendix, cecum, ascending 
colon, and up to the hepatic flexura, associating stripe thickening of adjacent fat. Multiple adenopathies containing 
calcifications and central necrosis. Fluid accumulation in the peritoneal cavity associating symmetrical, iodophilic 
thickening of parietal peritoneum. Osteolytic areas with an adjacent osteosclerotic reaction in L2, L3, and L4 vertebrae. 
Parafluid accumulation in L2–L3 and L3–L4 intervertebral spaces that reaches the anterior epidural space and the roots 
of L2 and L3 nerves, extending to L3–L4 adjacent smooth tissues, with no visible border toward the right psoas muscle.
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diagnosis. The presence of granulomas is typical for TB ascites [32]. The relative sensitivities 
of different procedures and the potential therapeutic benefits should be considered in mak-
ing the choice of diagnostic approach. In superficial TB lymphadenitis, fine needle aspiration 
(FNA) biopsy of affected lymph nodes is the gold-standard diagnostic technique. Excision 
biopsy has the highest sensitivity, whereas FNA is less invasive and may be useful. If FNA 
examination results are doubtful, excision biopsy may be needed. Laparoscopy with target 
peritoneal biopsy is the current first-line investigation in the diagnosis of peritoneal TB [33, 
34]. Several studies revealed a diagnostic accuracy of 84–96% for TB peritonitis.
Generally, tissue biopsy is superior to fluid aspiration in providing positive culture results. 
The diagnosis is more accurate when the biopsy results and polymerase chain reaction assays 
are combined with culture results [35].
5. Differential diagnosis
The main differential diagnosis is peritoneal carcinomatosis, which can be difficult to distin-
guish, especially in older patients. The nodules of carcinomatosis are larger, usually more 
than 3 mm, more vascular, and more irregular than the tuberculous ones which rarely surpass 
1–2 mm. Carcinomatosis is seen as an irregular peritoneal thickening with nodular implants, 
while TB peritonitis is suggested by the presence of a smooth peritoneum with symmetrical 
thickening, ascites, and enlarged lymph nodes of low attenuation [31].
Other less likely considerations include:
• Ascites in liver diseases: the liver is enlarged and irregular; proteins are lower than 4 g%.
• Nephrotic syndrome: ascites is less marked; proteins are lower than 4 g%.
• Nutritional edema (hypoproteinemia) has many other signs of protein deficiency; proteins 
are also lower than 4 g%.
• Starch peritonitis, sarcoidosis, and Crohn’s disease may resemble the laparoscopic features 
of TB peritonitis, but the presence of caseating granuloma establishes the diagnosis (Table 2) 
[36, 37].
The most important differential diagnosis Less likely considerations






Table 2. Differential diagnosis.
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There are a few signs that additionally suggest the diagnosis of TB peritonitis: normal serum 
levels of CA 19–9 and carcinoembryonic antigen (CEA), elevated serum levels of CA 125, fever, 
and lymphocyte-predominant benign ascites, but only biopsies yield the final diagnosis [38, 39].
6. Treatment
Treatment is initiated not only in patients with confirmed diagnosis but also in patients with 
strong suspicion of TB, because a delay in treatment initiation can lead to significant mor-
tality. TB treatment initiation includes also individuals with ascites associated with fever, 
weight loss, imaging signs of TB, personal history of TB, or contact with a tuberculosis case.
Despite the fact that most guidelines on the treatment of tuberculosis suggest that 6 months 
of treatment is sufficient for extrapulmonary tuberculosis (except for the case of bone tuber-
culosis or tuberculous meningitis), most physicians treating peritoneal tuberculosis use anti-
tuberculous therapy for 9 to 12 months [40, 41].
Drug treatment is the most important modality and follows standard regimens and prin-
ciples. There are currently five drugs that are considered first-line medications: isonia-
zid, rifampicin, pyrazinamide, streptomycin, and ethambutol. Second-line drugs are only 
used in case of resistance to first-line therapy (extensively drug-resistant tuberculosis or 
multidrug-resistant tuberculosis), and they are represented by aminoglycosides, fluoro-
quinolones, polypeptides, cycloserine, thioamides, and terizidone. There is also a third-
line therapy with uncertain or unproven efficacy including rifabutin, macrolides, linezolid, 
thioacetazone, thioridazine, arginine, bedaquiline, and vitamin D [42]. Drug-resistant dis-
ease varies substantially in different areas of the world and may occur in cases of poor 
patient management, nonadherence to prescribed regimen, or as a result of malabsorption 
of the antituberculous drugs.
The treatment of TB peritonitis in patients with HIV is usually the same, but because HIV-
infected patients are often taking multiple drugs, some of which may interact with antituber-
culous ones; it is strongly recommended to consult the experts in HIV-related TB.
The “complete response” to antituberculous treatment means complete resolution of symp-
toms and ascites within 6 months; in most cases, laboratory tests return to normal values 
within 3 months. Persistence of ascites means “no response” [43, 44].
7. Conclusions
Peritoneal tuberculosis is still common in areas of the world where TB is prevalent and its 
incidence ratio is likely to increase as a consequence of population migrations.
Ascites can be a complication of an aggregate of diseases, which carries an unfavorable prognosis 
that depends on the causes, the moment of diagnosis, and the start of the treatment.
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Establishing the diagnosis of TB ascites requires a high index of suspicion because of its insid-
ious development. In any patient with several weeks of abdominal pain, weight loss, fever, 
and lymphocytic dominant ascites with SAAG < 1.1 g/L, as well as in patients with ascites 
belonging to special population groups, such as indigenous or older people, or patients with 
ascites as the primary symptom, ascitic TB peritonitis should be considered in differential 
diagnosis. This syndrome behaves clinically like many abdominal diseases that are often 
ignored, leading to a significant impact on morbidity and mortality due to a delayed diag-
nosis and treatment. Older laboratory tests lack sensitivity and specificity in establishing the 
diagnosis. Histological examination, considered the gold-standard diagnosis method, is an 
invasive procedure with high risk of complications. More accurate methods such as molecular 
tests based on mycobacterial nucleic acid amplification tests (NAATs), PCR techniques used 
to detect bacterial DNA, or interferon-gamma release assays (IGRA) and biochemical meth-
ods such as the serum-ascites albumin gradient (SAAG), ratio between LDH in ascites fluid/
serum total protein (TP) ratio and fluid ascites/serum LDH ratio, adenosine deaminase activ-
ity (ADA), and imagistic techniques were recently considered for an efficient positive diagno-
sis of TB ascites, making possible the early treatment with appropriate tuberculostatic drugs.
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